Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uma Mylavarapu

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Cardiac Failure|December 1, 2025
Refining Atrial Shunt Therapy for HFpEF: Lessons from Pivotal Randomized Trials and Emerging DirectionsDylan J Gyberg, Jan Komtebedde, Uma Mylavarapu, et al.
JACC. Advances|September 2, 2025
Epicardial adipose tissue, functional status and invasive hemodynamics in heart failure with preserved ejection fractionYoran Crum, Dirk J van Veldhuisen, Sanjiv J Shah, et al.
Circulation. Population Health and Outcomes|January 19, 2026
Estimating the Placebo Effect on Patient-Reported Outcomes in Sham-controlled Device Trials: Insights from REDUCE LAP-HF IIAndrew A Girard, Uma Mylavarapu, Jan Komtebedde, et al.
JACC. Heart Failure|June 10, 2026
Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF: Insights From REDUCE LAP-HF IIShunichi Doi, Sho Kazui, Naoyuki Akashi, et al.
JACC. Heart Failure|December 3, 2025
Rationale and Design of the HeartShare/AMP-HF Deep Phenotyping Study to Improve Understanding of Heart Failure With Preserved Ejection FractionBarry A Borlaug, Julio A Chirinos, Gregory D Lewis, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Cardiac Failure|December 1, 2025
Refining Atrial Shunt Therapy for HFpEF: Lessons from Pivotal Randomized Trials and Emerging DirectionsDylan J Gyberg, Jan Komtebedde, Uma Mylavarapu, et al.
JACC. Advances|September 2, 2025
Epicardial adipose tissue, functional status and invasive hemodynamics in heart failure with preserved ejection fractionYoran Crum, Dirk J van Veldhuisen, Sanjiv J Shah, et al.
Circulation. Population Health and Outcomes|January 19, 2026
Estimating the Placebo Effect on Patient-Reported Outcomes in Sham-controlled Device Trials: Insights from REDUCE LAP-HF IIAndrew A Girard, Uma Mylavarapu, Jan Komtebedde, et al.
JACC. Heart Failure|June 10, 2026
Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF: Insights From REDUCE LAP-HF IIShunichi Doi, Sho Kazui, Naoyuki Akashi, et al.
JACC. Heart Failure|December 3, 2025
Rationale and Design of the HeartShare/AMP-HF Deep Phenotyping Study to Improve Understanding of Heart Failure With Preserved Ejection FractionBarry A Borlaug, Julio A Chirinos, Gregory D Lewis, et al.
Pageof 1